Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 14/20 | 0.69 |
| ▸ | GSK3B | P49841 | 3/20 | 0.69 |
| ▸ | WNT1 | P04628 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089886 | 0.96 | DYRK1A (0.64) | DYRK1AGSK3BWNT1NPC1RAB9A | |
| SCHEMBL2089883 | 0.96 | DYRK1A (0.64) | DYRK1AGSK3BWNT1NPC1RAB9A | |
| SCHEMBL2087004 | 0.91 | DYRK1A (0.61) | DYRK1AGSK3BALDH1A1CYP3A4TSHR | |
| SCHEMBL2088141 | 0.88 | DYRK1A (0.70) | DYRK1AGSK3BWNT1ALDH1A1CYP3A4 | |
| SCHEMBL2086418 | 0.87 | GSK3B (0.56) | DYRK1AGSK3BALDH1A1CYP3A4TSHR | |
| SCHEMBL12441864 | 0.87 | GSK3B (0.56) | DYRK1AGSK3BALDH1A1CYP3A4TSHR | |
| SCHEMBL2086417 | 0.87 | GSK3B (0.56) | DYRK1AGSK3BALDH1A1CYP3A4TSHR | |
| SCHEMBL2088104 | 0.87 | DYRK1A (0.69) | DYRK1AGSK3BWNT1 | |
| SCHEMBL2087377 | 0.85 | GSK3B (0.67) | DYRK1AGSK3B | |
| SCHEMBL2087375 | 0.85 | GSK3B (0.67) | DYRK1AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742944-B1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2010-11-10 | — | — | EP | claimed |
| US-20050250808-A1 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICAL CORPORATION | 2005-11-10 | — | — | US | claimed |
| US-20110178075-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2011-07-21 | — | — | US | disclosed |
| US-20110178075-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2011-07-21 | — | — | US | disclosed |
| US-7902217-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902217-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902217-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1742944-B1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2010-11-10 | — | — | EP | disclosed |
| EP-1742944-B1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20090118232-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-05-07 | — | — | US | disclosed |
| US-20090118232-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-05-07 | — | — | US | disclosed |
| US-20090118232-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-05-07 | — | — | US | disclosed |
| US-7488737-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICAL CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488737-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICAL CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488737-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICAL CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20050250808-A1 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICAL CORPORATION | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178075-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA2 | DYRK1A 1558/4885GSK3B 920/4885WNT1 1334/4885 |
| US-20050250808-A1 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA2 | DYRK1A 1558/4885GSK3B 920/4885WNT1 1334/4885 |
| US-20090118232-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA2 | DYRK1A 1558/4885GSK3B 920/4885WNT1 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.